U.S. markets closed
  • S&P Futures

    4,269.00
    -7.75 (-0.18%)
     
  • Dow Futures

    33,923.00
    -40.00 (-0.12%)
     
  • Nasdaq Futures

    13,455.75
    -37.50 (-0.28%)
     
  • Russell 2000 Futures

    1,987.60
    -1.50 (-0.08%)
     
  • Crude Oil

    87.68
    -0.43 (-0.49%)
     
  • Gold

    1,779.90
    +3.20 (+0.18%)
     
  • Silver

    19.76
    +0.03 (+0.17%)
     
  • EUR/USD

    1.0188
    +0.0008 (+0.08%)
     
  • 10-Yr Bond

    2.8930
    +0.0690 (+2.44%)
     
  • Vix

    19.90
    +0.21 (+1.07%)
     
  • GBP/USD

    1.2052
    +0.0000 (+0.00%)
     
  • USD/JPY

    134.8300
    -0.2600 (-0.19%)
     
  • BTC-USD

    23,441.91
    -549.98 (-2.29%)
     
  • CMC Crypto 200

    557.33
    -15.48 (-2.70%)
     
  • FTSE 100

    7,515.75
    -20.31 (-0.27%)
     
  • Nikkei 225

    28,892.85
    -329.92 (-1.13%)
     

Arcus Biosciences Announces New Employment Inducement Grants

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

HAYWARD, Calif., July 26, 2022--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the Compensation Committee of the Company’s Board of Directors granted six new employees options to purchase a total of 10,200 shares of the Company’s common stock at an exercise price per share of $26.19 which was the closing price on July 25, 2022, and restricted stock units to acquire a total of 5,100 shares of the Company’s common stock. The equity awards were granted pursuant to the Company’s 2020 Inducement Plan, which was approved by the Company’s Board of Directors in January 2020 pursuant to the "inducement exception" under NYSE Listed Company Manual Rule 303A.08.

About Arcus Biosciences

Arcus Biosciences is a clinical-stage, global biopharmaceutical company developing differentiated molecules and combination medicines for people with cancer. In partnership with industry partners, patients and physicians around the world, Arcus is expediting the development of first- or best-in-class medicines against well characterized biology and pathways and studying novel, biology-driven combinations that have the potential to help people with cancer live longer. Founded in 2015, the company has expedited the development of six investigational medicines into clinical studies, including new combination approaches that target TIGIT, PD-1, the adenosine axis (CD73 and dual A2a/A2b) and most recently, HIF-2alfa. For more information about Arcus Biosciences’ clinical and pre-clinical programs, please visit www.arcusbio.com or follow us on Twitter.

Inducement PR

Source: Arcus Biosciences

View source version on businesswire.com: https://www.businesswire.com/news/home/20220726005328/en/

Contacts

Investor and Media Inquiries:
Holli Kolkey
VP of Corporate Communications
(650) 922-1269
hkolkey@arcusbio.com